市場調査レポート

商品コード

1521213

抗肥満薬市場レポート：薬剤クラス別、薬剤タイプ別、流通チャネル別、地域別、2024年～2032年

Anti-Obesity Drugs Market Report by Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs), Drug Type (Prescription Drugs, OTC Drugs), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2024-2032

出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 430,566円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 574,136円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 717,706円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の抗肥満薬の市場規模は2023年に23億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに55億米ドルに達し、2024年から2032年の間に10.3％の成長率（CAGR）を示すと予測しています。

抗肥満薬は、体重の減少やコントロールを目的とするもので、一般に病的な肥満の場合にのみ医学的に処方されます。特に甘いものや脂肪分、塩分、高カロリーの食品に対する欲求を抑え、強迫的な摂食をコントロールするのに役立ちます。また、血圧、有害脂質値、ウエスト周囲径、糖度、非アルコール性脂肪性肝疾患（NAFLD）をコントロールし、主要な心血管疾患（CVD）のリスクや糖尿病性腎臓病の進行を最小限に抑えるなど、独立した健康上の利益をもたらすことができます。

抗肥満薬市場動向：

最近の抗肥満薬の進歩により、臨床的に有意な体重減少を達成できる可能性が出てきました。このことは、座りがちなライフスタイルのために肥満が広く蔓延していることと相まって、市場の見通しを明るくする重要な要因の一つとなっています。さらに、肥満は2型糖尿病（T2D）、心血管疾患（CVD）、食道、結腸・直腸、肝臓、胆嚢、膵臓、腎臓のがんの発症リスクを高める。また、多くの精神疾患、神経疾患、肺疾患、胃腸疾患、腎疾患、筋骨格系疾患、内分泌疾患を引き起こす可能性があります。これに加えて、睡眠不足、概日リズムの狂い、慢性的なストレス、抗てんかん薬や向精神薬の使用増加などが、体重増加をさらに誘発する可能性があります。このことは、食欲や食への欲求を調整する抗肥満薬（AOMs）の承認件数の増加と相まって、市場の成長に拍車をかけています。これとは別に、減量は個人の生活の質、運動能力、日常生活機能、心理的幸福の向上に役立ちます。これに加えて、健康志向の高まり、製薬業界の繁栄、過剰体重と密接に関連する疾患の管理への注目の高まりが、市場の成長を刺激すると予想されます。

本レポートで扱う主な質問

2023年の世界の抗肥満薬市場の市場規模は？
2024～2032年の世界の抗肥満薬市場の予想成長率は？
世界の抗肥満薬市場を牽引する主要因は？
世界の抗肥満薬市場に与えたCOVID-19の影響は？
世界の抗肥満薬市場の薬剤クラス別内訳は？
世界の抗肥満薬市場の薬剤タイプ別内訳は？
世界の抗肥満薬市場の主要地域は？
世界の抗肥満薬市場の主要プレイヤー／企業は？

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場動向
- 市場内訳：国別
- 市場予測

第10章 SWOT分析

概要
強み
弱み
機会
脅威

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第13章価格分析

第14章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Boehringer Ingelheim International GmbH
- Currax Pharmaceuticals LLC
- Gelesis
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Norgine B.V.
- Novo Nordisk A/S
- Pfizer Inc.
- Rhythm Pharmaceuticals Inc.
- SHIONOGI & Co. Ltd.
- Takeda Pharmaceutical Company Limited
- Vivus LLC

図表

List of Figures

Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2023
Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2023
Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2023
Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2023
Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
Table 7: Global: Anti-Obesity Drugs Market: Key Players

Product Code: SR112024A5544

The global anti-obesity drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 10.3% during 2024-2032.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, drug type, and distribution channel.

Breakup by Drug Class:

Peripherally Acting Drugs

Centrally Acting Drugs

Breakup by Drug Type:

Prescription Drugs

OTC Drugs

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report

1. What was the size of the global anti-obesity drugs market in 2023?
2. What is the expected growth rate of the global anti-obesity drugs market during 2024-2032?
3. What are the key factors driving the global anti-obesity drugs market?
4. What has been the impact of COVID-19 on the global anti-obesity drugs market?
5. What is the breakup of the global anti-obesity drugs market based on the drug class?
6. What is the breakup of the global anti-obesity drugs market based on the drug type?
7. What is the breakup of the global anti-obesity drugs market based on distribution channel?
8. What are the key regions in the global anti-obesity drugs market?
9. Who are the key players/companies in the global anti-obesity drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Anti-Obesity Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Peripherally Acting Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Centrally Acting Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Drug Type

7.1 Prescription Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 OTC Drugs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Pharmacy
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Boehringer Ingelheim International GmbH
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Currax Pharmaceuticals LLC
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 Gelesis
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 GlaxoSmithKline plc
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Merck & Co. Inc.
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Norgine B.V.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Novo Nordisk A/S
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Pfizer Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
- 14.3.9 Rhythm Pharmaceuticals Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
- 14.3.10 SHIONOGI & Co. Ltd.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Takeda Pharmaceutical Company Limited
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 Vivus LLC
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio

抗肥満薬市場レポート：薬剤クラス別、薬剤タイプ別、流通チャネル別、地域別、2024年～2032年

Anti-Obesity Drugs Market Report by Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs), Drug Type (Prescription Drugs, OTC Drugs), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2024-2032

抗肥満薬市場動向：

本レポートで扱う主な質問

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の抗肥満薬市場

第6章 市場内訳：薬剤クラス別

第7章 市場内訳：薬剤タイプ別

第8章 市場内訳：流通チャネル別

第9章 市場内訳：地域別

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格分析

第14章 競合情勢

List of Figures

List of Tables

Anti-Obesity Drugs Market Trends:

Key Market Segmentation:

Breakup by Drug Class:

Breakup by Drug Type:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Anti-Obesity Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Drug Type

8 Market Breakup by Distribution Channel

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

第1章序文

第2章調査範囲と調査手法

第3章エグゼクティブサマリー

第4章イントロダクション

第5章世界の抗肥満薬市場

第6章市場内訳：薬剤クラス別

第7章市場内訳：薬剤タイプ別

第8章市場内訳：流通チャネル別

第9章市場内訳：地域別

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章価格分析

第14章競合情勢